M&A/Shareholder vote/2026/Scipher Medicine Corporation

Scipher Medicine Corporation CMMB

Snowdrift Parent Corporation is buying Scipher Medicine Corporation (CMMB), paying holders in stock. Scipher Medicine Corporation develops precision medicine platforms including PrismRA diagnostic and SPECTRA platform for immunology and AI-enabled Network Medicine capabilities.

Holders get
Stock
Deal value
Not given
Expected close
Not given
Status
Pending
Checked
See the filing →

Filed

The deal

Snowdrift Parent Corporation will acquire Scipher Medicine Corporation, which develops precision medicine platforms including PrismRA diagnostic and SPECTRA platform for immunology and AI-enabled Network Medicine capabilities, in a stock transaction.

The deal is expected to close in the fourth calendar quarter of 2026, subject to completion of the Domestication Merger, a Concurrent PIPE Investment of at least $30,000,000, Nasdaq listing approval, and shareholder approval at the December 4, 2026 vote.

What has happened

Agreement signed · Chemomab Therapeutics Ltd., Scipher Medicine Corporation and Snowdrift Parent Corporation entered into an Agreement and Plan of Merger. · See the filing
Terms changed · See the filing
Terms changed · Amendment No. 2 to the merger agreement reduced the Combined Company's outstanding shares from 10,000,000 to 5,000,000 and amended the CVR Agreement information rights. · See the filing
Holders sent the terms and a meeting date

What must happen first

Domestication Merger completion
Concurrent PIPE Investment of at least $30,000,000
Nasdaq listing approval
shareholder approval

The board says

unanimously recommends that shareholders vote FOR all Proposals